ProCE Banner Activity

IMPAACT 2010 Update: Comparable Safety and Efficacy With DTG + FTC/TAF or FTC/TDF vs EFV/FTC/TDF at 50 Wks Postpartum Following Initiation in Pregnancy

Slideset Download
Conference Coverage

In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.

Released: March 11, 2021

Expiration: March 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare